Dynamic Antibody Industry

Aug 2005| BIO016F| BCC Publishing

Report Highlights

  • The worldwide market for therapeutic and diagnostic antibodies is estimated at $15 billion in 2005 and will rise at an average annual growth rate (AAGR) of 11.5% to nearly 26 billion in 2010.
  • Therapeutic antibodies dominate the market and are projected to have an AAGR of 11.4%, reaching $25.7 billion in 2010.
  • The therapeutic monoclonal antibody segment will rise at an AAGR of 12.4% while the therapeutic polyclonal market, driven more by volume and demand than innovation, is projected to see an AAGR of only 4%.
  • The diagnostic imaging market, though small, will experience an average annual growth near 17%, reaching $147 million in 2010.

INTRODUCTION

Monoclonal antibody drugs offer several advantages over other types of drugs. Technologically, antibodies exhibit amazing specificity that allows for a safe and targeted attack on disease-causing cells or compounds. The antibody itself may be used as a weapon or the antibody may serve as the vehicle to deliver a drug. Along with high specificity, monoclonal antibodies are effective in a broad range of diseases including autoimmune, cardiovascular and infectious diseases, cancer and inflammation. Also of great importance is that antibodies are virtually never toxic.

As of May 2005, there were 18 therapeutic monoclonal antibody products on the U.S. market. Worldwide, there were an estimated 500 monoclonal antibody products in development by more than 200 companies for the treatment of virtually every debilitating disease. Approximately 80 of these were in clinical trials.

This BCC report provides detailed market analyses and industry trends. It quantifies and qualifies the emerging market for monoclonal and polyclonal antibody drugs and imaging products. Forecasts and trends are gleaned from industry sources as well as from considered assessments of available and emerging technologies. The study also examines strategies used by biotechnology companies and pharmaceutical firms to develop and market products in this explosive market sector.

SCOPE OF STUDY

The report contains:

 

  • A discussion of the importance and advantages of antibody-based products, patent issues and applicability
  • Analysis of antibody technology, research and production, and the types of antibodies used as therapeutics or diagnostics
  • A synopsis of more than 100 monoclonal and polyclonal antibody drugs and diagnostic imaging products currently marketed and those in Phase II or later development
  • Comparative product and sales analyses, including current and forecasted sales through 2010 by individual product, target and technology, as well as worldwide market size and growth estimates
  • An overview of the leading indications for available and emerging antibody-based therapeutics and diagnostics
  • Profiles of leading companies and those with emerging products or technologies.

 

METHODOLOGY

The base year for this study is 2005. Figures are based on revenue figures at the manufacturers' level and are projected at 2005-dollar value; that is, inflation is not computed into the projection figures.

Information to prepare this study was derived from information obtained from product managers, marketing strategists, research executives and others at leading pharmaceutical and biotechnology companies that compete in the market for antibody drugs and imaging diagnostics or which have products in development for this market.

INFORMATION SOURCES

The information and analyses presented in this report are based on an extensive survey of the biotechnology and pharmaceutical industries as well as a detailed examination of published literature and reports obtained from regulatory authorities, medical research institutions, pharmaceutical trade associations and national and world health organizations. Key information from the literature was used to obtain expert opinion on commercial potential and market sizes from industry professionals.

ANALYST'S CREDENTIALS

Lynn Gray has been a research analyst in the biotechnology and life sciences since 1989. Her collaboration with Communications Co. (BCC) began in 1996, and during that time, she has authored over 20 BCC biomedical reports.

Frequently Asked Questions (FAQs)

Table of Contents

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at info@bccresearch.com
Title/Chapter NamePagesMember Price
Full Report: Dynamic Antibody Industry257Free
Chapter- 1: INTRODUCTION4Free
Chapter- 2: SUMMARY2Free
Chapter- 3: OVERVIEW8Free
Chapter- 4: TECHNOLOGY45Free
Chapter- 5: PRODUCTS91Free
Chapter- 6: APPLICATIONS38Free
Chapter- 7: INDUSTRY STRUCTURE11Free
Chapter- 8: C. CRAMER & CO. GMBH58Free
Published - Oct-2002| Analyst - Lynn Gray| Code - BIO016E

Report Highlights

  • As of May 2002, there were 11 therapeutic monoclonal antibody products on the U.S. market. Worldwide, there were an estimated 470 monoclonal antibody products in development by more than 200 companies for the treatment of virtually every debilitating disease. Approximately 70 of these monoclonal antibody products were in clinical trials. According to the Pharmaceutical Research and Manufacturers of America (PhRMA), monoclonal antibody products represented approximately 20% of all products in development and 33% of all biotech products in development by its members.
  • The therapeutic monoclonal antibody market is projected to have an average annual growth rate (AAGR) of approximately 25% throughout the forecast period. The therapeutic polyclonal antibody market, which is driven more by volume and demand than innovation, is projected to see an AAGR of just less than 11%. The diagnostic imaging market, though small, will see average annual growth exceeding 28% throughout the forecast period.

Published - Feb-2000| Analyst - Lynn Gray| Code - BIO016D

Report Highlights

  • Antibody-based drugs, in particular monoclonal antibody-based products, are on the brink of significant commercial growth. New developments are spurred in part by advances in technology that have now surmounted previous technical barriers to commercialization.
  • The information and analyses presented in this report on antibody-based drugs is an important asset in decision-making for managers involved in development, marketing, market research, product development, mergers and acquisitions, licensing, management, investment banking and deal creation, and to consultants to the pharmaceutical and biotechnology industry.
  • The study provides a comprehensive analysis of the current markets for antibody drugs and, in particular, the market potential of promising drugs and technologies under development.

Dynamic Antibody Industry

Single User License: $2750

Become a Member

Already a member? Login to access this report free.

Have a Question? Ask Us.

Why BCC Research.?

Every purchase provides access to:

  • Thousands of recently published reports from select publishers
  • Member Discounts of up to 50% on over 20,000 additional reports from all publishers
  • Our analysts and research concierge for all inquiries
RELATED REPORTS